Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1192

1.

Measuring the quality of colorectal cancer screening: the importance of follow-up.

Etzioni DA, Yano EM, Rubenstein LV, Lee ML, Ko CY, Brook RH, Parkerton PH, Asch SM.

Dis Colon Rectum. 2006 Jul;49(7):1002-10.

PMID:
16673056
2.

The use of screening colonoscopy for patients cared for by the Department of Veterans Affairs.

El-Serag HB, Petersen L, Hampel H, Richardson P, Cooper G.

Arch Intern Med. 2006 Nov 13;166(20):2202-8.

PMID:
17101937
3.

A randomized trial of direct mailing of fecal occult blood tests to increase colorectal cancer screening.

Church TR, Yeazel MW, Jones RM, Kochevar LK, Watt GD, Mongin SJ, Cordes JE, Engelhard D.

J Natl Cancer Inst. 2004 May 19;96(10):770-80.

PMID:
15150305
4.

Cost-effectiveness of colonoscopy in screening for colorectal cancer.

Sonnenberg A, Delcò F, Inadomi JM.

Ann Intern Med. 2000 Oct 17;133(8):573-84.

PMID:
11033584
5.

Impact of comorbidity on colorectal cancer screening in the veterans healthcare system.

Fisher DA, Galanko J, Dudley TK, Shaheen NJ.

Clin Gastroenterol Hepatol. 2007 Aug;5(8):991-6. Epub 2007 Jul 12.

PMID:
17627900
6.
7.

Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy.

Winawer SJ, Flehinger BJ, Schottenfeld D, Miller DG.

J Natl Cancer Inst. 1993 Aug 18;85(16):1311-8.

PMID:
8340943
8.

Validity of four self-reported colorectal cancer screening modalities in a general population: differences over time and by intervention assignment.

Jones RM, Mongin SJ, Lazovich D, Church TR, Yeazel MW.

Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):777-84. doi: 10.1158/1055-9965.EPI-07-0441. Epub 2008 Apr 1.

9.

Effect of Medicare coverage on use of invasive colorectal cancer screening tests.

Ko CW, Kreuter W, Baldwin LM.

Arch Intern Med. 2002 Dec 9-23;162(22):2581-6.

PMID:
12456230
10.

Timely follow-up of positive fecal occult blood tests strategies associated with improvement.

Powell AA, Gravely AA, Ordin DL, Schlosser JE, Partin MR.

Am J Prev Med. 2009 Aug;37(2):87-93. doi: 10.1016/j.amepre.2009.05.013. Epub 2009 Jun 12.

PMID:
19524390
11.

Colorectal cancer screening in young patients with poor health and severe comorbidity.

Sultan S, Conway J, Edelman D, Dudley T, Provenzale D.

Arch Intern Med. 2006 Nov 13;166(20):2209-14.

PMID:
17101938
12.

Validation of self-reported colorectal cancer screening behavior from a mixed-mode survey of veterans.

Partin MR, Grill J, Noorbaloochi S, Powell AA, Burgess DJ, Vernon SW, Halek K, Griffin JM, van Ryn M, Fisher DA.

Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):768-76. doi: 10.1158/1055-9965.EPI-07-0759. Epub 2008 Apr 1.

13.

Colorectal carcinoma screening procedure use among primary care patients.

Lafata JE, Williams LK, Ben-Menachem T, Moon C, Divine G.

Cancer. 2005 Oct 1;104(7):1356-61.

14.

Colorectal cancer screening mode preferences among US veterans.

Powell AA, Burgess DJ, Vernon SW, Griffin JM, Grill JP, Noorbaloochi S, Partin MR.

Prev Med. 2009 Nov;49(5):442-8. doi: 10.1016/j.ypmed.2009.09.002. Epub 2009 Sep 8.

PMID:
19747502
15.

Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood.

Mandel JS, Church TR, Ederer F, Bond JH.

J Natl Cancer Inst. 1999 Mar 3;91(5):434-7.

PMID:
10070942
16.

Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.

Worthley DL, Smith A, Bampton PA, Cole SR, Young GP.

Eur J Gastroenterol Hepatol. 2006 Oct;18(10):1079-83.

PMID:
16957514
17.

Barriers to full colon evaluation for a positive fecal occult blood test.

Fisher DA, Jeffreys A, Coffman CJ, Fasanella K.

Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1232-5.

18.
19.
20.

Supplemental Content

Support Center